John N. Allan, MD, an assistant attending physician at NewYork-Presbyterian Hospital and an assistant professor of medicine at Weill Cornell Medical College of Cornell University, discusses a pooled analysis of 4 clinical trials with 4-year follow-up of first-line ibrutinib (Imbruvica) in patients with chronic lymphocytic leukemia (CLL) and TP53 aberration deletion 17p or a TP53 mutation.
The main outcomes being investigated in the analysis were progression-free survival (PFS), overall survival (OS), response rate, and safety. All 89 patients had TP53 disruption, a median age of 65 years, and 69% had unmutated IGHV. They all had fluorescence in situ hybridization analysis available, which showed that 53% of the patients had deletion 17p. Not all patients had sequencing available, but they found that 58 of the 89 subjects had sequencing results available and of those, 91% patients were positive for the mutation and were included in this study, according to Allan. The median follow-up was for 15 months on ibrutinib.
The ILLUMINATE (NCT02264574)and the EGOG1912 (NCT02048813)trials incorporated Ibrutinib plus either rituximab (Rituxan) or obinutuzumab (Gazyva). Allan says it was a mixed population in terms of the ibrutinib-based therapy; the other studies were using monotherapy only. Approximately half of the patients were treated with monotherapy and half were treated with anti-CD20 therapy.
The long-term outcome of 4-year PFS rate was 79% and the 4-year OS rate was 88%. Allan feels the results were impressive and showed that while these patients historically have done very poorly, they appear to be doing pretty well and overcoming some of this high-risk features of their disease biology.
Acalabrutinib/Obinutuzumab Shows Improved PFS in Treatment-Naive CLL
April 10th 2024In an interview with Targeted Oncology, Jeff Sharman, MD, discussed the results of the ELEVATE-TN trial of acalabrutinib with or without obinutuzumab at 74.5 months of follow-up among patients with chronic lymphocytic leukemia.
Read More
Behind the FDA Approval of Liso-cel for Relapsed/Refractory CLL/SLL
March 15th 2024In an interview with Targeted Oncology, Tanya Siddiqi, MD, discussed the rationale behind the TRANSCEND CLL 004 study supporting the FDA approval of lisocabtagene maraleucel in chronic lymphocytic leukemia or small lymphocytic lymphoma.
Read More